One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory

Interventions

DRUG

JCXH-213,an mRNA-LNP based in vivo CAR therapy

JCXH-213 infusion

Trial Locations (1)

RECRUITING

Department of Lymphoma and Myeloma, Yuhengnan Road, Changping District, Beijing, Beijing

All Listed Sponsors

collaborator

Ruijin Hospital

OTHER

lead

Beijing GoBroad Hospital

OTHER